Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE vs COLESEVELAM HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Adjunctive therapy to diet and exercise for reduction of elevated LDL cholesterol in adults with primary hyperlipidemia,Monotherapy or combination therapy for homozygous familial hypercholesterolemia,Adjunctive therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Pediatric primary hyperlipidemia
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Not applicable as colesevelam is not absorbed; it acts locally in the gastrointestinal tract.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Colesevelam is not systemically absorbed (<0.05%) and undergoes negligible metabolism.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Colesevelam is not absorbed systemically; it is excreted unchanged in the feces via biliary elimination. No renal excretion occurs.
Minimal (<10%) for most amino acids; not significantly protein-bound.
0% (not absorbed; no systemic protein binding).
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Not applicable; drug is not systemically absorbed and remains confined to the gastrointestinal lumen.
Intravenous: 100%.
<0.1% after oral administration; essentially not absorbed.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
No dose adjustment required for renal impairment; not systemically absorbed.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
No dose adjustment required for hepatic impairment.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Not approved for pediatric patients; safety and efficacy not established.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
No specific dose adjustment; use with caution due to potential for constipation and gastrointestinal obstruction.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
No FDA black box warning.
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
May cause hypertriglyceridemia (monitor triglycerides),Risk of fat-soluble vitamin deficiency (Vitamins A, D, E, K) with prolonged use,May reduce absorption of: oral contraceptives, cyclosporine, warfarin, thyroid hormone, and other drugs (administer 4 hours before or after Colesevelam),Patients with hemorrhoids or history of severe GI obstruction risk,May cause constipation, dyspepsia, and abdominal pain
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
Bowel obstruction or history of bowel obstruction,Hypertriglyceridemia-induced pancreatitis,Elevated serum triglycerides >500 mg/d L,Hypersensitivity to colesevelam or any component
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
Take with meals to enhance bile acid binding. Avoid high-fat meals that may reduce efficacy. Colesevelam may interfere with absorption of fat-soluble vitamins (A, D, E, K); consider supplementation if long-term use. Grapefruit juice has no documented interaction.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Colesevelam hydrochloride is not systemically absorbed (<0.05% oral bioavailability). No fetal risk is expected. No adequate and well-controlled studies in pregnant women. Based on animal studies, no evidence of harm at doses up to 1.5 times human dose. Insufficient data for first trimester; however, given negligible absorption, teratogenic risk is considered negligible across all trimesters.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Colesevelam is not absorbed systemically; therefore, excretion into breast milk is negligible. M/P ratio: not applicable. Considered compatible with breastfeeding by most sources.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
No dosing adjustment is necessary. Colesevelam's pharmacokinetics are unaffected by pregnancy due to negligible systemic absorption. Dose should be based on clinical response to hyperlipidemia. Standard adult dosing: 3 tablets (625 mg each) twice daily or 6 tablets once daily with food and liquid.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
Colesevelam is a bile acid sequestrant that reduces LDL-C and improves glycemic control in type 2 diabetes. Administer with meals to maximize bile acid binding. Monitor triglycerides as levels may increase. Separate dosing from other medications (e.g., levothyroxine, warfarin) by at least 4 hours to avoid reduced absorption. Can be mixed with water, fruit juice, or soft foods.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
Take this medication with a meal and at least 4 hours after any other medications.,Mix powder with 4-8 ounces of water, fruit juice, or soft food (e.g., applesauce) and consume within 24 hours.,Do not take without food; it may cause stomach upset.,Common side effects include constipation, gas, and indigestion; drink plenty of fluids and increase fiber intake.,This medication can increase triglyceride levels; your doctor will monitor your blood.,Inform your doctor if you have a history of pancreatitis or gallbladder disease.,Keep out of reach of children and store at room temperature.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE vs COLESEVELAM HYDROCHLORIDE, answered by our medical review team.
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. COLESEVELAM HYDROCHLORIDE is a Bile Acid Sequestrant that works by Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE and COLESEVELAM HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. The standard adult dose of COLESEVELAM HYDROCHLORIDE is: 3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE and COLESEVELAM HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. COLESEVELAM HYDROCHLORIDE is classified as Category A/B. Colesevelam hydrochloride is not systemically absorbed (<0.05% oral bioavailability). No fetal risk is expected. No adequate and well-controlled studies in pregnant women. Based on. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.